| アブストラクト | Background: In the phase 3 clinical trials FIGARO-DKD and FIDELIO-DKD, finerenone reduced the risk of cardiovascular and kidney events among people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence regarding finerenone use in real-world settings is limited. Methods: A retrospective cohort study (NCT06278207) using two Japanese nationwide hospital-based databases provided by Medical Data Vision (MDV) and Real World Data Co., Ltd. (RWD Co., Kyoto Japan), converted to the OMOP common data model, was conducted. Persons with CKD and T2D initiating finerenone from 1 July 2021, to 30 August 2023, were included. Baseline characteristics were described. The occurrence of hyperkalemia after finerenone initiation was assessed. Results: 1029 new users of finerenone were included (967 from MDV and 62 from RWD Co.). Mean age was 69.5 and 72.4 years with 27.3% and 27.4% being female in the MDV and RWD Co. databases, respectively. Hypertension (92 and 95%), hyperlipidemia (59 and 71%), and congestive heart failure (60 and 66%) were commonly observed comorbidities. At baseline, 80% of persons were prescribed angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists were prescribed in 72% and 30% of the study population, respectively. The incidence proportions of hyperkalemia were 2.16 and 2.70 per 100 persons in the MDV and RWD Co. databases, respectively. There were no hospitalizations associated with hyperkalemia observed in either of the two datasets. Conclusions: For the first time, we report the largest current evidence on the clinical use of finerenone in real-world settings early after the drug authorization in Japan. This early evidence from clinical practice suggests that finerenone is used across comorbidities and comedications. |
|---|
| ジャーナル名 | Journal of clinical medicine |
|---|
| 投稿日 | 2024/9/14 |
|---|
| 投稿者 | Sato, Atsuhisa; Rodriguez-Molina, Daloha; Yoshikawa-Ryan, Kanae; Yamashita, Satoshi; Okami, Suguru; Liu, Fangfang; Farjat, Alfredo; Oberprieler, Nikolaus G; Kovesdy, Csaba P; Kanasaki, Keizo; Vizcaya, David |
|---|
| 組織名 | Department of Nephrology and Hypertension, International University of Health and;Welfare Shioya Hospital, Yaita 329-2145, Japan.;Integrated Evidence Generation & Business Innovation, Bayer AG, 13342 Berlin,;Germany.;Medical Affairs & Pharmacovigilance, Bayer Yakuhin Ltd., Breeze Tower, 2-4-9;Umeda, Kita-ku, Osaka 530-0001, Japan.;Division of Nephrology, Department of Medicine, University of Tennessee Health;Science Center, Memphis, TN 38163, USA.;Department of Internal Medicine 1, Faculty of Medicine, Shimane University, 89-1;Enya-cho, Izumo 693-8501, Japan.;Center for Integrated Kidney Research and Advance, Faculty of Medicine, Shimane;University, 89-1 Enya-cho, Izumo 693-8501, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39274317/ |
|---|
